Related Experiment Video
Updated: Jul 15, 2026

Cell Death Associated with Abnormal Mitosis Observed by Confocal Imaging in Live Cancer Cells
Published on: August 21, 2013
The cell cycle inhibitor p57(Kip2) promotes cell death via the mitochondrial apoptotic pathway
1Karolinska Institutet, Institute of Environmental Medicine, 171 77 Stockholm, Sweden.
Abstract:
The p57(Kip2) gene belongs to the Cip/Kip family of cyclin-dependent kinase (CDK) inhibitors and has been suggested to be a tumor suppressor gene, being inactivated in various types of human cancers. However, little is known concerning p57(Kip2) possible interplay with the apoptotic cell death machinery and its possible implication for cancer. Here, we report that selective p57(Kip2) expression sensitizes cancer cells to apoptotic agents such as cisplatin, etoposide and staurosporine (STS) via a mechanism, which does not require p57(Kip2)-mediated inhibition of CDK. Translocation of p57(Kip2) to mitochondria occurs within 20 min after STS application. In fact, p57(Kip2) primarily promotes the intrinsic apoptotic pathways, favoring Bax activation and loss of mitochondrial transmembrane potential, consequent release of cytochrome-c into cytosol, caspase-9 and caspase-3 activation. In accordance, Bcl2 overexpression or voltage-dependent anion channel (VDAC) inhibition is able to inhibit p57(Kip2) cell death promoting effect. Thus, in addition to its established function in control of proliferation, these results reveal a mechanism whereby p57(Kip2) influences the mitochondrial apoptotic cell death pathway in cancer cells.
Insights
The p57(Kip2) gene, a cyclin-dependent kinase inhibitor, sensitizes cancer cells to apoptosis. It promotes intrinsic cell death pathways by affecting mitochondria, independent of its cell cycle inhibition role.
Area of Science:
- Molecular Biology
- Cancer Biology
- Cell Death Research
Background:
- The p57(Kip2) gene is a cyclin-dependent kinase (CDK) inhibitor implicated as a tumor suppressor.
- Its role in apoptosis and cancer, beyond proliferation control, remains largely unexplored.
Purpose of the Study:
- To investigate the interplay between p57(Kip2) and apoptotic cell death pathways in cancer.
- To elucidate the mechanism by which p57(Kip2) influences cancer cell sensitivity to apoptosis.
Main Methods:
- Selective expression of p57(Kip2) in cancer cells.
- Treatment with apoptotic agents (cisplatin, etoposide, staurosporine).
- Analysis of mitochondrial translocation, Bax activation, mitochondrial potential, cytochrome-c release, and caspase activation.
Main Results:
- p57(Kip2) expression sensitizes cancer cells to apoptosis independently of CDK inhibition.
- p57(Kip2) translocates to mitochondria upon apoptotic stimulus.
- p57(Kip2) promotes intrinsic apoptosis via Bax activation, mitochondrial potential loss, and caspase cascade activation.
- Bcl2 overexpression or VDAC inhibition counteracts p57(Kip2)-induced cell death.
Conclusions:
- p57(Kip2) plays a significant role in promoting apoptosis through the intrinsic mitochondrial pathway in cancer cells.
- This function is distinct from its known role in cell proliferation control.
- p57(Kip2) represents a potential therapeutic target for enhancing cancer cell apoptosis.
More Related Videos
Related Concept Videos
The Intrinsic Apoptotic Pathway
DNA Damage can Stall the Cell Cycle
DNA Damage Can Stall the Cell Cycle
The Extrinsic Apoptotic Pathway
Negative Regulator Molecules
Inhibition of Cdk Activity

